Literature DB >> 8465831

Epidemiologic analysis of existing data to investigate hypertensive renal disease: an example from the Maryland End-Stage Renal Disease Registry.

F L Brancati1, P K Whelton, J C Whittle, M J Klag.   

Abstract

Observational epidemiology provides powerful methods for studying the etiology and natural history of renal disease in populations. Existing data sets can be used in the conduct of cross-sectional, case-control, and cohort studies that complement experimental investigations. Analysis of existing data sets is extremely efficient and, in many instances, provides results of similar quality to those derived from studies that depend on the collection of original data. A study based on linkage of hypertensive end-stage renal disease (ESRD) incidence rates from the Maryland Regional ESRD Registry with corresponding prevalence data from a state-wide survey of cardiovascular risk factors (The Maryland Statewide Household Hypertension Survey) illustrates the power, efficiency, and flexibility of observational epidemiologic methods in investigating racial differences in hypertensive ESRD. Such analyses can both test previously established hypotheses and generate new hypotheses for subsequent investigation.

Entities:  

Mesh:

Year:  1993        PMID: 8465831     DOI: 10.1016/s0272-6386(12)80857-2

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  2 in total

1.  The association of low birthweight and chronic renal failure among Medicaid young adults with diabetes and/or hypertension.

Authors:  Z Joyce Fan; Daniel T Lackland; Stuart R Lipsitz; Joyce S Nicholas
Journal:  Public Health Rep       Date:  2006 May-Jun       Impact factor: 2.792

2.  Association between circulating specific leukocyte types and incident chronic kidney disease: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Niu Tian; Alan D Penman; R Davis Manning; Michael F Flessner; Anthony R Mawson
Journal:  J Am Soc Hypertens       Date:  2011-11-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.